Gilead Sciences, Inc. ‘s ( GILD ) third quarter 2012 earnings (excluding special items but including stock option expense) of 95 cents per share beat the Zacks Consensus Estimate of 90
Sanofi ( SNY ) and its subsidiary Genzyme recently presented positive data on its oral treatment for relapsing forms of multiple sclerosis (RMS), Aubagio (teriflunomide). The company
Sigma-Aldrich Corporation ( SIAL ) announced a collaboration between Sigma Advanced Genetic Engineering (SAGE) Labs – an initiative of Sigma Life Science and Ekam Imaging, Inc.